MARKET

BIOA

BIOA

BioAge Labs Inc.
NASDAQ
10.60
+0.17
+1.63%
After Hours: 10.54 -0.06 -0.57% 19:40 08/14 EDT
OPEN
10.37
PREV CLOSE
10.43
HIGH
10.63
LOW
10.10
VOLUME
444.37K
TURNOVER
--
52 WEEK HIGH
25.96
52 WEEK LOW
4.250
MARKET CAP
486.51M
P/E (TTM)
-4.4437
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BIOA last week (0803-0807)?
Weekly Report · 5d ago
BioAge Labs price target lowered to $20 from $23 at Morgan Stanley
TipRanks · 08/07 13:39
Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV)
TipRanks · 08/06 23:40
Oppenheimer Sticks to Its Buy Rating for BioAge Labs, Inc. (BIOA)
TipRanks · 08/06 13:07
BioAge Labs: Upstream NLRP3 Strategy and Strong Cash Runway Underpin Unchanged $35 Price Target and Buy Rating
TipRanks · 08/06 12:25
Analysts Are Bullish on These NA Stocks: BillionToOne, Inc. Class A (BLLN), Carlsmed, Inc. (CARL)
TipRanks · 08/06 11:11
Andy Hsieh Reiterates Hold on BioAge as Strong Cash Runway Offsets Execution and Clinical Surrogate Uncertainties
TipRanks · 08/06 01:45
BioAge Labs reports Q2 EPS (58c), consensus (62c)
TipRanks · 08/05 23:00
More
About BIOA
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product is BGE-102, a structurally novel, orally available small molecule NLRP3 inhibitor with high potency and brain penetration. In preclinical obesity models, BGE-102 resulted in weight loss as both a monotherapy and in combination with a GLP-1R agonist. Its pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. In preclinical obesity models, APJ agonism has demonstrated the ability to more than double the weight loss induced by a GLP-1R agonist while also restoring healthy body composition and improving muscle function.

Webull offers BioAge Labs, Inc. stock information, including NASDAQ: BIOA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIOA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIOA stock methods without spending real money on the virtual paper trading platform.